Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 135)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bromides |
|
Phase 4 |
|
|
|
2 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
3 |
|
gamma-Globulins |
|
Phase 4 |
|
|
|
4 |
|
Rho(D) Immune Globulin |
|
Phase 4 |
|
|
|
5 |
|
Salbutamol |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
18559-94-9 |
2083 |
Synonyms:
(±)-SALBUTAMOL
(L)-Albuterol
1-(Tert-butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol
2-(Tert-butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol
2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol
4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol
ACCUNEB
Aerolin
AEROLIN 400
AEROLIN AUTO
AIROMIR
AIRSALB
Albuterol
Albuterol sulfate
Albuterol Sulphate
albuterol|SCH-13949W|Ventolin®
Almotex
Alpha'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
Alti-salbutamol
Anebron
Arubendol-salbutamol
Asmadil
Asmanil
Asmasal
ASMASAL CLICKHALER
ASMASAL SPACEHALER
Asmatol
Asmaven
ASMAVENT
Asmidon
Asmol
Asmol uni-dose
Asthalin
Asthavent
Broncho-spray
Broncovaleas
Bronter
BTA204
Bugonol
Bumol
Butamol
Buto-asma
Butohaler
Butotal
Butovent
Buventol
Cetsim
Cobutolin
COMBIVENT
COMBIVENT UDVS
Dilatamol
DL-Albuterol
DL-N-Tert-butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine
DL-Salbutamol
DUONEB
Ecovent
Farcolin
Gerivent
Grafalin
IPRAMOL STERI-NEB
KENTAMOL
Levalbuterol
LIBETIST
Libretin
Loftan
MAXIVENT
Medolin
Mozal
Novosalmol
Parasma
Pneumolat
ProAir
PROAIR HFA
Proventil
|
Proventil hfa
Proventil inhaler
PROVENTIL-HFA
Respax
Respolin
RIMASAL
Rotahaler
R-Salbutamol
Sabutal
Salamol
SALAMOL E-BREATHE
SALAPIN
Salbetol
Salbron
Salbu-basf
Salbu-fatol
Salbuhexal
Salbulin
SALBULIN NOVOLIZER
Salbupur
Salbusian
Salbutalan
SALBUTAMOL
Salbutamol free base
Salbutamol sulfate
Salbutamol sulphate
Salbutamolum
Salbutan
Salbutard
Salbutine
Salbutol
Salbuven
Salbuvent
SALIPRANEB
Sallbupp
Salmaplon
Salomol
Salvent
Saventol
SCH 13949W
SCH-13949W
Servitamol
Solbutamol
Spreor
STERI-NEB SALAMOL
Sultanol
Sultanol N
Suprasma
Suxar
Theosal
Tobybron
Vencronyl
Venetlin
Ventalin Inhaler
Ventamol
Ventilan
Ventiloboi
VENTMAX SR
Ventodisks
Ventolin
VENTOLIN CR
VENTOLIN E-BREATHE
VENTOLIN HFA
Ventolin inhaler
Ventolin rotacaps
Ventoline
Volare albuterol hfa
Volare easi-breathe
Volma
Volmax
Xopenex
Xopenex HFA
Zaperin
|
|
6 |
|
Eculizumab |
Approved, Investigational |
Phase 3 |
|
219685-50-4 |
|
Synonyms:
5G1.1
ABP-959
ECULIZUMAB
H5G1.1
|
H5G1.1VHC+H5G1.1VLC
H5G11
H5G1-1
SOLIRIS
|
|
7 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 3 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
8 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 3 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
9 |
|
Prednisolone |
Approved, Vet_approved |
Phase 3 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
10 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 3 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
11 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 3 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
12 |
|
Tacrolimus |
Approved, Investigational |
Phase 3 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
13 |
|
Cathine |
Approved, Experimental, Illicit, Vet_approved, Withdrawn |
Phase 3 |
|
14838-15-4, 492-39-7 |
131954576 4786 26934 |
Synonyms:
(+-)-Norephedrine
(+)-Norpseudoephedrine
(+-)-Phenylpropanolamine
2-AMINO-1-PHENYLPROPAN-1-OL
Cathina
Cathine
Cathinum
D-Cathine
Dexatrim
DL-Norephedrine
DL-Phenylpropanolamine
D-Norephedrine
d-Norpseudoephedrine
d-Nor-psi-ephedrine
FENILPROPANOLAMINA
Hydriatine
Hydrochloride, phenylpropanolamine
Katine
L-NOREPHEDRINE
L-Phenyl propanolamine
|
Mucorama
Nobese
NOREPHEDRIN
Norephedrine
Obestat
PHENYLPROPANOLAMIN
Phenylpropanolamina
Phenylpropanolamine
PHÉNYLPROPANOLAMINE
Phenylpropanolamine hydrochloride
PHENYLPROPANOLAMINUM
PPA
Prestwick_388
Prolamine
Propadrine
Propagest
Pseudonorephedrine
psi-Norephedrine
Triaminic DM
Β-HYDROXYAMPHETAMINE
|
|
14 |
|
Guaifenesin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
93-14-1 |
3516 |
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
Amonidren
Amonidrin
AMONIDRON
Aresol
Benylin-e
Breonesin
Bronchol
CVT-2534
Ether, guaiacol glyceryl
FAMEL
FRANOLYN CHESTY
GECOLATE
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl ether, guaiacol
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
Glycerylguaiacol
|
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolate, glycerol
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
GUAIFENESIN OR GUAIPHENESIN
Guaifenesina
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphenezine
Guaiphesin
Guiatuss
HUMABID
Humibid
Hustosil
Hytuss
LIQUFRUTA
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
MUCINEX
NIROLEX FOR CHESTY COUGH DECONGESTANT
NSC-62112
O-Methoxyphenyl glyceryl ether
Organidin NR
p-Cresyl acetate
Pneumomist
Propanosedyl
Reduton
Robitussin
Scott tussin
Scott-tussin
ScottTussin
TIXYLIX CHESTY COUGH
|
|
15 |
|
Azathioprine |
Approved |
Phase 3 |
|
446-86-6 |
2265 |
Synonyms:
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
Azamun
AZAMUNE
Azanin
AZAPRESS
Azasan
Azathioprin
AZATHIOPRINE
Azathioprine sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azatioprin
Azatioprina
|
Azothioprine
BERKAPRINE
BW-57-322
Ccucol
IMMUNOPRIN 50
Immuran
Imuran
IMURAN (TN)
Imurek
Imurel
KENTAPRINE
Muran
NSC-39084
OPRISINE 50
Sodium, azathioprine
|
|
16 |
|
Leflunomide |
Approved, Investigational |
Phase 3 |
|
75706-12-6 |
3899 |
Synonyms:
5-Methylisoxazole-4-carboxylate (4-trifluoromethyl)anilide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
a,a,a-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
ARABLOC
Arabloc®|Arava®|HWA 486|HWA-486|lefunamide|SU-101
Arava
Aventis behring brand OF leflunomide
Aventis brand OF leflunomide
Aventis pharma brand OF leflunomide
Hoechst brand OF leflunomide
HWA 486
HWA-486
|
L04AA13
Leflunomida
LEFLUNOMIDE
Léflunomide
Leflunomidum
Leflunomidum [INN-Latin]
LEFUNAMIDE
LEFUNOMIDE
Lefunomide [INN-Spanish]
N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
SU101
SU-101
SULOL
Α,α,α-trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
|
|
17 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
18 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
19 |
|
Acetylcholine |
Approved, Investigational |
Phase 3 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
20 |
|
Ravulizumab |
Approved, Investigational |
Phase 3 |
|
1803171-55-2 |
|
Synonyms:
ALXN1210
ALXN-1210
RAVULIZUMAB
|
RAVULIZUMAB-CWVZ
ULTOMIRIS
|
|
21 |
|
Prednisone |
Approved, Vet_approved |
Phase 3 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
22 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 3 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
23 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 3 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
24 |
|
Rozanolixizumab |
Investigational |
Phase 3 |
|
1584645-37-3 |
|
Synonyms:
CA170_01519.g57 IgG4P|UCB-7665|UCB7665
|
|
|
25 |
|
Adrenergic Agonists |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Adrenergic Agents |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Bronchodilator Agents |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Adrenergic beta-Agonists |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Anti-Asthmatic Agents |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Tocolytic Agents |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
32 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
33 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
34 |
|
Methylprednisolone Acetate |
|
Phase 3 |
|
|
584547 |
Synonyms:
Acetyl methylprednisolone
Acetyl-methylprednisolone
DEPMEDALONE
Depo medrol
Depo medrone
Depo-medrol
Depo-medrone
|
MEDROL ACETATE
Methylprednisolone 21 acetate
METHYLPREDNISOLONE ACETATE
Methylprednisolone acetate, (11beta,16alpha)-isomer
Methylprednisolone acetate, (11beta,16beta)-isomer
Methylprednisolone acetic acid
Methylprednisolone-21-acetate
|
|
35 |
|
Calcineurin Inhibitors |
|
Phase 3 |
|
|
|
36 |
|
Cholinesterase Inhibitors |
|
Phase 3 |
|
|
|
37 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
38 |
|
Antitubercular Agents |
|
Phase 3 |
|
|
|
39 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
40 |
|
Chlorpheniramine, phenylpropanolamine drug combination |
|
Phase 3 |
|
|
|
41 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
42 |
|
Antineoplastic Agents, Immunological |
|
Phase 3 |
|
|
|
43 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
44 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
45 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
46 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
47 |
|
Hormones |
|
Phase 3 |
|
|
|
48 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
49 |
|
glucocorticoids |
|
Phase 3 |
|
|
|
50 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 157)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis |
Unknown status |
NCT03510546 |
Phase 4 |
Pyridostigmine;Placebo oral capsule |
2 |
Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study |
Completed |
NCT00987116 |
Phase 4 |
Prednisone - Azathioprine |
3 |
A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis |
Completed |
NCT01179893 |
Phase 4 |
|
4 |
Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis |
Unknown status |
NCT03914638 |
Phase 2, Phase 3 |
Salbutamol 4Mg Tablet;Placebo oral capsule |
5 |
A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG) |
Unknown status |
NCT02950155 |
Phase 3 |
Rituximab;Sodium Chloride solution |
6 |
A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients |
Completed |
NCT03304054 |
Phase 3 |
Amifampridine Phosphate;Placebo Oral Tablet |
7 |
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness |
Completed |
NCT03770403 |
Phase 3 |
|
8 |
A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis |
Completed |
NCT04735432 |
Phase 3 |
|
9 |
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) |
Completed |
NCT01997229 |
Phase 3 |
Placebo |
10 |
A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis |
Completed |
NCT00515450 |
Phase 3 |
|
11 |
A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
Completed |
NCT04124965 |
Phase 3 |
Rozanolixizumab |
12 |
A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) |
Completed |
NCT02301624 |
Phase 3 |
Placebo |
13 |
A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone |
Completed |
NCT00408213 |
Phase 3 |
mycophenolate mofetil [CellCept];Placebo |
14 |
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis |
Completed |
NCT00683969 |
Phase 3 |
mycophenolate mofetil (CellCept);placebo |
15 |
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis |
Completed |
NCT04115293 |
Phase 3 |
zilucoplan (RA101495);Placebo |
16 |
A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations |
Completed |
NCT02413580 |
Phase 3 |
|
17 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness |
Completed |
NCT03669588 |
Phase 3 |
|
18 |
FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients |
Completed |
NCT00309088 |
Phase 3 |
tacrolimus;placebo |
19 |
IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial |
Completed |
NCT00306033 |
Phase 3 |
Intravenous ImmuneGlobulin |
20 |
A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone |
Completed |
NCT00294658 |
Phase 3 |
prednisone alone |
21 |
A Trial of Mycophenolate Mofetil in Myasthenia Gravis |
Completed |
NCT00285350 |
Phase 3 |
mycophenolate mofetil |
22 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
Completed |
NCT03971422 |
Phase 3 |
Rozanolixizumab |
23 |
A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy |
Completed |
NCT01325571 |
Phase 3 |
Tacrolimus capsule;Placebo |
24 |
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy |
Completed |
NCT01727193 |
Phase 3 |
Azathioprine;Leflunomide |
25 |
FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients |
Completed |
NCT00309101 |
Phase 3 |
tacrolimus |
26 |
A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan |
Recruiting |
NCT05514873 |
Phase 3 |
zilucoplan (RA101495) |
27 |
A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation |
Recruiting |
NCT02774239 |
Phase 3 |
Human normal immunoglobulin G (IgG) |
28 |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis |
Recruiting |
NCT05556096 |
Phase 3 |
|
29 |
Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis |
Recruiting |
NCT04833894 |
Phase 2, Phase 3 |
|
30 |
An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis |
Recruiting |
NCT05265273 |
Phase 2, Phase 3 |
Nipocalimab |
31 |
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis |
Recruiting |
NCT05332587 |
Phase 3 |
Rituximab |
32 |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG) |
Recruiting |
NCT05132569 |
Phase 3 |
Tolebrutininb;Placebo |
33 |
A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis |
Recruiting |
NCT05374590 |
Phase 2, Phase 3 |
|
34 |
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis |
Recruiting |
NCT04951622 |
Phase 3 |
Nipocalimab;Placebo |
35 |
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis |
Recruiting |
NCT04524273 |
Phase 3 |
inebilizumab;IV Placebo |
36 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis |
Recruiting |
NCT04963270 |
Phase 3 |
Satralizumab |
37 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Seamless and Group Sequential Phase 2/3 Study to Evaluate the Efficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis |
Recruiting |
NCT05039190 |
Phase 3 |
HBM9161 Injection (680mg);Placebos |
38 |
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG) |
Recruiting |
NCT05403541 |
Phase 3 |
Batoclimab 680 mg SC weekly;Batoclimab 340 mg SC weekly;Matching Placebo SC;Batoclimab 340 mg SC bi-weekly |
39 |
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis |
Recruiting |
NCT05070858 |
Phase 3 |
Pozelimab + Cemdisiran;Cemdisiran;Pozelimab |
40 |
A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis |
Recruiting |
NCT04980495 |
Phase 3 |
|
41 |
An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis |
Active, not recruiting |
NCT03759366 |
Phase 3 |
Eculizumab |
42 |
An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis |
Active, not recruiting |
NCT04650854 |
Phase 3 |
Rozanolixizumab |
43 |
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis |
Active, not recruiting |
NCT04225871 |
Phase 3 |
zilucoplan (RA101495) |
44 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis |
Active, not recruiting |
NCT03920293 |
Phase 3 |
Placebo |
45 |
Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis |
Active, not recruiting |
NCT03579966 |
Phase 3 |
Amifampridine Phosphate |
46 |
A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis |
Active, not recruiting |
NCT04818671 |
Phase 3 |
|
47 |
A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis |
Not yet recruiting |
NCT05332210 |
Phase 3 |
HBM9161 Injection (680mg);HBM9161 Drug Product (340mg) |
48 |
Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study |
Terminated |
NCT00995722 |
Phase 3 |
Prednisone;Placebo |
49 |
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis. |
Withdrawn |
NCT03165435 |
Phase 2, Phase 3 |
|
50 |
Ephedrine for the Treatment of Congenital Myasthenia |
Unknown status |
NCT00541216 |
Phase 1, Phase 2 |
Ephedrine |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cyclophosphamide
Cyclosporine
Neostigmine
Neostigmine bromide
|
Neostigmine Methylsulfate
Pyridostigmine
Pyridostigmine Bromide
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
|